An Amgen executive refutes accusations that the company published misleading results of its mid-90s clinical trial testing an anemia drug.
Advertisement
News & Opinion
Covering the life sciences inside and out
Most Recent
People are currently driving the planet on a crash course with global stability. Something must be done.
Financial “conflicts of interest” should not be so quickly condemned. Industry relationships are unequivocally beneficial.
African justice systems must change to help curb HIV and tuberculosis transmission in prisons.
Engaging the brain with cognitive tasks helps paralyzed rats walk again.
A 30-year-old technique to record the electrical activity of neurons gets a robotic makeover.
Is the push for science to save the still flailing economy a threat to scientific research?
Neurons injected into mice help treat chronic pain at its roots, rather than simply alleviating its symptoms.
Successful conservation depends on an economy that doesn’t incentivize destruction of species and habitats.
Amgen’s incomplete report on an early major trial of epoetin misled the medical community about the anemia drug’s risks and benefits—and helped make Amgen rich.
Subjects
- cancer
- cell & molecular biology
- culture
- disease/medicine
- ecology
- evolution
- genetics & genomics
- neuroscience
- opinion
- techniques
Sub Categories
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
